Microvascular Endothelial Cell Responses in vitro and in vivo: Modulation by Zoledronic Acid and Paclitaxel? | Zendy

Maria Michailidou | Zendy; Hannah K. Brown | Zendy; Diane V. Lefley | Zendy; Alyson Evans | Zendy; Simon S. Cross | Zendy; Robert E. Coleman | Zendy; Nicola J. Brown | Zendy; Ingunn Holen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Microvascular Endothelial Cell Responses in vitro and in vivo: Modulation by Zoledronic Acid and Paclitaxel?

Author(s) -

Maria Michailidou,

Hannah K. Brown,

Diane V. Lefley,

Alyson Evans,

Simon S. Cross,

Robert E. Coleman,

Nicola J. Brown,

Ingunn Holen

Publication year - 2010

Publication title -

journal of vascular research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.58

H-Index - 74

eISSN - 1423-0135

pISSN - 1018-1172

DOI - 10.1159/000313876

Subject(s) - paclitaxel , in vivo , zoledronic acid , apoptosis , pharmacology , endothelial stem cell , angiogenesis , cell growth , cancer research , chemistry , in vitro , medicine , biology , biochemistry , cancer , microbiology and biotechnology

The cytotoxic agent paclitaxel and the anti-resorptive drug zoledronic acid are used in the early and advanced breast cancer setting, respectively. Both agents have been demonstrated to have anti-tumour and anti-endothelial actions. Combining paclitaxel with zoledronic acid induces a synergistic increase in apoptotic breast cancer cell death in vitro, suggesting an increased anti-tumour effect in vivo, but any specific effects on the normal microvasculature and potential side-effects of this combination remain to be established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research